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Schistosomiasis is a parasitic disease spread by fresh water snails. After malaria, schistosomiasis is the 
deadliest parasitic disease, plaguing an estimated 200 million people worldwide, and causing up to 280,000 
fatalities in Africa.  This neglected tropical disease has also emerged as an important co-factor in Africa’s 
HIV/AIDS epidemic, especially among women and adolescent girls.  Together with hookworm disease and 
leishmaniasis, it ranks as the neglected tropical disease with the highest disease burden as defined by disability-
adjusted life years (DALYs)1.  Although treatments exist, such as praziquantel chemotherapy, a vaccine will 
likely be needed to prevent infection and re-infection, interrupt disease transmission, and ultimately establish 
long-term control and elimination of the disease.  No such vaccine currently exists, but a promising candidate is 
currently under development at Texas Children’s Hospital Center for Vaccine Development (TCH-CVD). 
 
The Sm-TSP-2 schistosomiasis vaccine comprises a 9 kDa recombinant protein corresponding to the 
extracellular domain of a unique S. mansoni tetraspanin found in the parasite’s tegumental surface. Sm-TSP-2 
was expressed as a recombinant protein secreted by the yeast PichiaPinkTM and purified in a two-step process, 
which resulted in a protein recovery yield of 31% and a protein purity of 97%.2 The developed processes were 
suitable for production of purified protein for subsequent formulation and Phase 1 clinical studies.  However, 
improvements in process yield and efficiency, as well as transition of the formulation to GMP-compatible 
materials, are desirable for the advancement of this candidate through subsequent clinical phases and large-
scale manufacturing. 
 
TCH-CVD and MilliporeSigma are conducting a collaborative project to optimize the efficiency and scalability of 
the Sm-STP-2 schistosomiasis vaccine manufacturing process.  The overall goal of this work is to develop a 
safe and low-cost process for the purification of the vaccine antigen.  This was accomplished by redesigning the 
original process, which utilized 750kD hollow fiber and 3kD cellulose membrane tangential flow filtration (TFF) 
devices for the clarification and concentration of the Pichia pastoris-based vaccine lysate process feed.  The 
level of solids in the fermentation broth (30%) had required a dilution to enable processing through the hollow 
fiber device, which led to decreased product yield and increased complexity.   
 
MilliporeSigma assisted TCH-CVD with studies to eliminate the dilution prior to lysate clarification and to also 
streamline the process to enable Texas Children’s to simultaneously clarify and concentrate the yeast lysate.   
0.1um, open-channel, stacked plate, membrane sheet TFF devices were successfully used to clarify the 
undiluted lysate.  The TFF operating parameters (specifically the feed and permeate flow rates) were optimized 
to enable the downstream 3kD concentration process to run concurrently in a cascade TFF.  Enhancement of 
the chromatography operations is currently underway as well.  This presentation will detail the optimized 
clarification and concentration process and highlight the economic and process simplification benefits.   
Work was also performed to optimize the vaccine formulation. Extensive studies were previously conducted to 
identify excipients and conditions to maximize the stability of soluble recombinant Sm-TSP-2.3   Additional 
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